One of the main research areas in biology from the mid-1980s through the 1990s was the elucidation of signaling pathways governing cell responses. These studies brought, among other molecules, the small GTPase Rho to the epicenter. Rho signaling research has since expanded to all areas of biology and medicine. Here, we describe how Rho emerged as a key molecule governing cell morphogenesis and movement, how it was linked to actin reorganization, and how the study of Rho signaling has expanded from cultured cells to whole biological systems. We then give an overview of the current research status of Rho signaling in development, brain, cardiovascular system, immunity and cancer, and discuss the future directions of Rho signaling research, with emphasis on one Rho effector, ROCK.*

*The Rho GTPase family. Rho family GTPases have now expanded to contain 20 members. Amino acid sequences of 20 Rho GTPases found in human were aligned and the phylogenetic tree was generated by ClustalW2 software (EMBL-EBI) based on NJ algorithm. The subfamilies of the Rho GTPases are highlighted by the circle and labeled on the right side. Rho cited in this review refers to the original members of Rho subfamily, RhoA, RhoB and RhoC, that are C3 substrates, and, unless specified, not to other members of the Rho subfamily such as Rac, Cdc42, and Rnd.

Keywords: actin; actomyosin; C3 exoenzyme; myosin; Rho; ROCK; SRF; Y-27632

Abbreviations
ECM, extracellular matrix; LPA, lysophosphatidic acid; MLC, myosin light chain; MRTF, myocardin-related transcription factor; PBMCs, peripheral blood mononuclear cells; ROCK, Rho-associated coiled-coil containing kinase; SRF, serum response factor.
Discovery of Rho and botulinum C3 exoenzyme; the dawn of Rho research

In the mid-1980s, there was a transition in signal transduction research. While prototypes of transmembrane signaling such as heterotrimeric G proteins and G-protein coupled receptors, receptor tyrosine kinases, channels and transporters, had been identified and cloned, little was known about how the signals transmitted within the cell evoke cell responses such as proliferation, exocytosis and adhesion. Although involvement of GTP in some of these responses was reported, molecules bearing such GTP-dependent functions were far from identification. An exception was Ras, which had been identified as retrovirus-coded oncogenes encoding a 21 kDa GTP-binding protein, but its action mechanism also remained an enigma. In this situation, Madaule and Axel serendipitously identified the first Ras homolog in Aplysia, and named it Rho [1]. They further detected Rho genes in human and rat, and suggested that those of human possibly consist of three members, which were later named RhoA, B, and C. However, without any biological findings, little attention was paid to it.

One approach to discover mechanisms and principles working in biological processes is to find out pharmacological tools interfering with such processes by specifically targeting the molecules involved. Given the demonstrated usefulness of cholera toxin and pertussis toxin as probes of heterotrimeric G-proteins, Gs and Gi/Go, respectively [2] and the fact that most of the bacterial toxin ADP-ribosyltransferases target GTP-binding proteins [2], we sought a novel bacterial ADP-ribosyltransferase activity, and identified in preparations of botulinum C1 and D toxin an enzyme that ADP-ribosylates a 22 kDa GTP-binding protein in mammalian cells. We reported these findings in the *Journal of Biological Chemistry* on February 5, 1987 [3]. To our surprise, the same enzyme activity was reported in the February 9, 1987, issue of *FEBS Letters* by Aktories and collaborators [4]. They later further reported that this ADP-ribosyltransferase is distinct from botulinum neurotoxins and named it C3 exoenzyme [5]. Almost 1 year later, Rubin et al. confirmed these findings and additionally reported that the C3 treatment induced morphological changes in cultured cells, typically the rounding up of fibroblasts and epithelial cells and the neurite extension of neuronal cells [6], which we also noted separately [7,8]. However, the identity of the target GTP-binding protein was not elucidated until we purified and identified it as Rho [9–11]. Our studies thus merged researches on Rho and C3. Chardin et al. then reported that actin microfilaments were lost in C3-treated round-up Vero cells [12]. The next question was therefore how the morphological phenotype of C3-treated cells is related to the function of Rho and how Rho is involved in actin microfilament assembly. Because little was known about the difference between the Rho isoforms, most of the early studies in the field were focused on RhoA.

Rho as a molecular switch for actin cytoskeleton reorganization

According to the analogy to Ras, it was thought that Rho is activated from the GDP-bound form to the GTP-bound form to exert its actions. So, the above question could be addressed by comparing the C3 phenotype with that induced by active Rho. This was exactly where Alan Hall and collaborators entered the field, using their expertise in Ras biochemistry and microinjection technique. They microinjected Val14-RhoA, a presumably active RhoA mutant with reduced GTPase activity, and found extensive actin filament assembly in the contracted body of microinjected cells [13]. Although this Val14-RhoA phenotype appeared opposite to the above phenotype of C3-treated cells, it was not clear at this time what kind of cell structures and what kind of cell response they represent. Ridley and Hall addressed these points [14]. They showed that the actin filament structure induced by active RhoA in fibroblasts represents actin stress fibers linked to focal adhesions, that these structures are induced by the addition of serum to the cells, and that this induction was inhibited by microinjection of C3 or ADP-ribosylated Rho, thus making clear that Rho works as a molecular switch in stimulus-induced stress fiber formation. By this time, homology cloning and protein purification identified a variety of Ras-related GTP-binding proteins in mammals and yeast. Didsbury et al. [15] isolated two cDNAs highly homologous to Rho from HL-60 kibrary, and erroneously named Rac (Ras-related C3 substrate) 1 and 2. Ridley and Hall therefore extended their study to examine the function of Rac1, and reported that Rac1 induces a different actin filament structure, membrane ruffles, in response to PDGF [16]. Their works thus established the paradigm that Rho GTPases function as molecular switches for actin reorganization.

Focal adhesion induced by Rho is the multi-protein complex of integrin and associated proteins, which is clustered by the force of actomyosin bundles ligated
to this complex, and serves as adhesion to extracellular matrix (ECM). Therefore, Rho-induced focal adhesion formation facilitates cell adhesion to ECM by increasing the integrin avidity. We confirmed RhoA action with platelet aggregation as an example, which is mediated by binding of platelet integrin GPIIb/IIIa to soluble ECM ligands such as fibrinogen [17].

Other notable examples of Rho-regulated cell processes were neurite retraction and cytokinesis. In the above work on stress fibers, Ridley and Hall identified a major RhoA activating factor in serum as lysophosphatidic acid (LPA). The biological activity of this lipid was found by Wouter Moolenaar, who also found that the addition of LPA induces neurite retraction in neuroblastoma cells. Hearing his talk at our Department seminar, we noticed that this LPA phenotype was opposite to neurite extension by the C3 treatment. We therefore collaborated and found that RhoA mediates neurite retraction induced by LPA [18]. We also collaborated with Issei Mabuchi on the role of Rho in cytokinesis, and found that the C3 treatment aborted cytokinesis by abolishing the contractile ring, indicating that Rho links nuclear division to cytoplasmic division through induction of the contractile ring [19]. Kishi et al. analyzed the division of Xenopus embryos and reached the same conclusion [20].

intriguingly, Treisman and collaborators found that LPA also activates the transcription factor “serum response factor” (SRF) and this activation also requires functional RhoA [21]. Their later studies showed that SRF activity is regulated by SRF transcriptional coactivator myocardin-related transcription factor (MAL/MRTF) and that the interaction between SRF and MAL/MRTF is inhibited by the binding of MAL/MRTF to G-actin [22]. Upon RhoA activation, G-actin is incorporated into F-actin and MAL/MRTF is subsequently released from G-actin. This facilitates the formation of SRF-MAL/MRTF complexes and thus the activation of SRF-dependent transcription of genes that are involved in a variety of cellular processes such as cell migration, cell proliferation and cell differentiation [23].

**Search and identification of Rho effectors; elucidation of molecular mechanisms of Rho actions**

Both stress fibers and the contractile ring are composed of actomyosin bundles and neurite retraction is caused by their contraction. These findings led us to hypothesize that the action of Rho is to make actin filaments from actin monomers and then cross-link them by activating myosin for contraction. So, the next issue of Rho research was to find out molecules and mechanisms underlying these steps, which are presumably carried out by effector molecules downstream of Rho. Since the GTP-bound and not GDP-bound Rho exerts its actions, effector molecules were presumed to bind selectively to the GTP-bound Rho. Isolation of small GTPase effectors by such selective binding was heralded by Louis Lim and collaborators, who isolated p65PAK (PAK1) as a Cdc42/Rac effector in 1994 [24]. Using selective binding to the GTP-bound Rho in ligand overlay assay or yeast two hybrid systems, we isolated several Rho effectors [25–29]. One of them is Rho-associated coiled-coil containing kinase (ROCK), which consists of two isoforms, ROCK-I (ROCK1) and ROCK-II (ROCK2) [26,30]. The same enzymes were isolated and called ROK and Rho-kinase by Louis Lim’s group [31] and Kozo Kaibuchi’s group [32], which correspond to ROCK-I and ROCK-II, respectively. Another effector we isolated was a mammalian homolog of Diaphanous (mDia) [29], which belongs to the formin family and consists of three isoforms [33]. Expression of active ROCK produced actomyosin bundles reminiscent of stress fibers and extensive formation of focal adhesions in HeLa cells [34,35] presumably through activation of myosin (see below), and expression of active mDia increased the density of actin filaments [29], suggesting that it induces actin polymerization. The actin nucleation/polymerization activity of the formin family was later shown in yeast formin, Bni1p [36] and then mDia [37]. Co-expression of ROCK and mDia produced beautifully aligned stress fibers in HeLa cells, thus reproducing the action of Rho on stress fiber formation [38]. Thus, mDia and ROCK are thought as main effectors in Rho-induced actin reorganization (Fig. 1).

**Discovery of Y-27632, a specific ROCK inhibitor; a pivotal point from cell biology to physiology**

Smooth muscle contraction is triggered by myosin light chain (MLC) phosphorylation. The involvement and mechanism of ROCK in myosin activation was revealed both biochemically and pharmacologically by the analysis of the so called “calcium-sensitization pathway” of smooth muscle contraction. This pathway augments contraction at a fixed intracellular calcium ion concentration [Ca^{2+}], and was previously demonstrated to involve GTP, RhoA and myosin phosphatase [39,40]. Kaibuchi’s group showed that Rho kinase/ROCK phosphorylates myosin-binding subunit of myosin phosphatase, thus inactivating the
phosphatase and consequently raising MLC phosphorylation and contraction [41]. The involvement of ROCK in this process was also confirmed pharmacologically using Y-27632. Y-27632 was developed as a compound that inhibits the calcium-sensitization pathway of smooth muscle contraction, and the photo-affinity cross-linking and the assay on recombinant ROCK identified it as a selective ROCK inhibitor [42]. This inhibitor not only inhibited the calcium-sensitization of smooth muscle selectively but also abolished RhoA-induced formation of stress fibers and focal adhesions. This compound further inhibits the RhoA-mediated neurite retraction in neuroblastoma cells and analysis of this effect revealed the RhoA-mediated inhibition of actin depolymerization through the ROCK-LIM kinase-cofilin pathway [43]. Thus, identification of Rho effectors and a ROCK-specific inhibitor facilitated elucidation of molecular mechanisms of Rho-mediated cellular responses. The impact of the discovery of Y-27632, however, was not limited to analysis of cultured cells but also on intact animals, in which Y-27632 is used to examine possible involvement of Rho-ROCK signaling in various physiological and pathophysiological processes as described below. Thus, the discovery of Y-27632 made a pivotal point in Rho research.

Fig. 1. (A) Simplified scheme depicting the actions of mDia and ROCK in Rho-mediated actin remodeling. Upon the activation by Rho, mDia promotes actin nucleation and polymerization to form actin filaments and ROCK activates myosin to bundles actin filaments. The upper right box shows the FH1FH2 of mDia1-catalyzed actin polymerization in vitro. Red arrowheads indicate the mDia1-free barbed end of F-actin growing at slow rate, and blue arrowheads indicate the barbed end undergoing mDia1 (FH1FH2)-dependent fast growth. Times are indicated in seconds. Scale bar, 5 μm. Modified from Yamashiro S, et al. MBoC 25, 1010–1024 (2014). The lower right box shows F-actin staining of HeLa cells overexpressing vector control or active ROCK-I. Note that F-actin bundles are extensively induced in active ROCK-I overexpressed cells. Modified from Ishizaki T, et al. FEBS Lett. 404, 118–124 (1997). (B) Crystal structures of Y-27632-bound (left) and fasudil-bound (right) kinase domain of ROCK-I. Modified from Jacobs M, et al. JBC 281, 260–268 (2006).
**Rho signaling research in current status**

With the spread of the knowledge on Rho signaling in various cell processes and the advent of various dissecting tools, that is, drugs, expression constructs, RNAi and transgenic, and knockout animals, Rho signaling research has spread widely to all areas of biology. Here, we select several fields and overview their current status.

**Development and regeneration**

Rho signaling functions critically in several developmental processes (Fig. 2). Its typical mode of action here is to form actomyosin bundles traversed intercellularly by connecting neighboring epithelial cells through cell-cell adhesion and contract them for tissue morphogenesis and maintenance. Both ROCK and mDia are involved. For example, mice-deficient in either ROCK-I or ROCK-II fail in closure of the eyelid and the ventral body wall and are born with the ‘eyes open at birth’ and omphalocele phenotype. In these mice, actin cables that encircle the eye in the epithelial cells of the eyelid as well as those encircling the umbilical ring are disorganized [44–46]. Although each of ROCK-I and ROCK-II exhibits distinct roles in many circumstances described below, they apparently act functionally redundant in these closure processes. In mDia1/3 double KO mice, apical actin belts in neuroepithelial cells were attenuated and their apical adherens junctions were impaired, resulting in the loss of apical-basal polarity of neuroepithelial cells and periventricular hyperplasia [47]. When such apical actomyosin cables contract, it causes apical constriction of epithelial cells and, making cuboidal cells to trapezoid, bending tissues and forming three-dimensional structures such as tube and invagination. This is seen in gastrulation and neurulation, where Rho, ROCK and mDia function [48]. In chick neural tube formation, cadherin, Celsr1, recruits PDZ-RhoGEF at the mediolateral adherens junctions to upregulate Rho-ROCK signaling and cause actomyosin contraction apically in a planar-polarized manner [49,50]. A similar role of Rho-ROCK signaling in planar cell polarity was reported in Drosophila germ band extension [51]. Furthermore, ROCK functions also in making convex invagination in optic-cup-like structure formation from ES cells in culture [52]. In addition, the polarized localization of ROCK causes biased actomyosin activity in a single cell, and this mechanism operates crucially in asymmetric cell division of Drosophila neural stem cells [53].

YAP and TAZ are effectors of the Hippo signaling involved in control of organ size, stem cell renewal, regeneration and cancer [54]. They are also involved in mechanotransduction, and translocate to the nucleus on sensing of ECM stiffness and cell spreading in Rho- and actomyosin tension-dependent manners [55]. Requirement of Rho signaling is also observed in activation of YAP/TAZ by Wnt signaling, in which Wnt activates Rho through FZD-ROR-Gz12/13 pathway and inhibits Lats1/2 [56]. This Rho-mediated activation of YAP/TAZ is required for long-term survival and expansion of human ES cells cultured en bloc [57]. Interestingly and paradoxically, dissociated human ES cells exhibit Rho-ROCK-mediated hyperactivation of myosin and the resultant contraction induces their death, which can be rescued by Y-27632 [58–60].

**Brain morphogenesis and function**

Rho signaling is involved in brain morphogenesis and functions including axonogenesis, neuronal migration and synaptic plasticity. Neurite retraction in cultured neuron is mediated by ROCK [61,62] and ROCK2 KO mice exhibited enhanced axonogenesis after spinal cord injury and recovered faster than the control mice [63]. The Rho-ROCK signaling is now recognized as the final common pathway to limit axonogenesis in CNS trauma and the potential of ROCK inhibitor in axonal regeneration is being examined [64]. Notably, this Rho-ROCK action operates in not only such pathophysiological process but also neuronal development. Kaibuchi’s group recently showed that the growing axon transmits long-range Ca^{2+} waves to other neurites, activates RhoA-ROCK pathway there and suppresses their axonogenesis to allow the formation of a single axon in neurons [65]. Rho signaling also works in neuronal migration; mice deficient in mDia1 and 3 in combination exhibit deficit in tangential migration of interneuron precursors from subventricular zone to the olfactory bulb [66]. Moreover, Rho signaling plays critical roles in synaptic plasticity. The dendritic spine is the site of memory. Rac and Rho work antagonistically in shaping dendritic spines, growth and shrinkage, respectively, and ROCK mediates the latter Rho action [67]. By this action, ROCK apparently is involved in some types of mental retardation, where a Rho GTPase activating protein named oligophrenin-1 is mutated; down-regulation of oligophrenin-1 results in spine shrinkage, which is rescued by ROCK inhibitor [68]. In addition to these postsynaptic actions, ROCK functions in synaptic vesicle retrieval in the presynaptic terminal to contribute to the homeostatic balance of vesicle exocytosis and
endocytosis at synapse [69]. Furthermore, Rho signaling is involved in plasticity of the presynaptic terminal. Deguchi et al. [70] found that social isolation of mice induces inactivation of Nucleus accumbens neurons, which then leads to mDia and ROCK-dependent contraction of their terminals in the Ventral tegmental area and reduces synaptic transmission there, which causes enhanced anxiety behavior in these animals. These actions of Rho-ROCK signaling could be involved in synaptic plasticity in the lateral amygdala associated with fear conditioning as well as that in pre-limbic prefrontal cortex associated with goal-directed decision making, both of which is sensitive to ROCK inhibition [71,72].

**Cardiovascular system**

Since Y-27632 was discovered through screening for compounds that inhibit calcium sensitization of arterial contraction and shown to lower blood pressure in various rat models of hypertension [42], much interest has arisen naturally in the role of Rho-ROCK signaling in the cardiovascular system. Such interest was boosted further by the finding that fasudil, a drug...
approved in Japan for treatment of vasospasm after subarachnoid hemorrhage, is also a ROCK inhibitor [73], which has stimulated studies not only in animals but also in humans. For example, fasudil is effective in decreasing the frequency of attacks in stable angina patients [74] and attenuating coronary artery vasospasm in patients with vasoplastic angina, the effect reproduced in the porcine model with enhanced myosin phosphatase activation [75]. These findings led to the proposal of a role of ROCK in coronary vasospasm. In idiopathic pulmonary hypertension, ROCK2 is highly expressed in pulmonary arteries of patients and fasudil treatment induces acute pulmonary vasodilation [76]. Consistently, the selective loss of ROCK2 in vascular smooth muscle prevents development of chronic hypoxia-induced pulmonary hypertension in mice, suggesting the causative relation of ROCK2 in this disease. Other studies using ROCK1 and ROCK2 KO mice and ROCK inhibitors in various animal models indicate the involvement of ROCK in diabetic vasculopathy, ischemia/reperfusion injury, heart failure, cardiac hypertrophy, and fibrosis [77]. Interestingly, in aortic constriction model, the cardiomyocyte-specific deletion of ROCK2 suppressed the cardiac hypertrophy [78], while the ROCK1 haploinsufficiency did not prevent cardiac hypertrophy but reduced fibrosis under the same condition [79]. A profibrotic role of ROCK is also reported in various organs including lung [80].

**Immunity**

Early studies on the role of Rho in the immune system focused on its role in development, activation and migration of T cells and B cells [81]. For example, studies on mice expressing C3 or active RhoA in T cell lineages suggested that RhoA is important in thymocyte expansion but dispensable for T cell development itself [82,83]. Indeed, deficiency of RhoA in T cells does not completely suppress but significantly attenuates in T cell receptor-dependent proliferative response [84]. Inactivation of Rho and treatment with ROCK inhibitors impairs T cell migration. The most notable feature is deficit in transendothelial migration due to impaired uropod retraction [85], a feature shared with neural precursors, macrophages, neutrophils and cancer cells [66,86–88]. Recent studies have focused more on the role of ROCK in the differentiation of T helper cell (Th) subsets and its pathological significance [89]. Rho-ROCK signaling appears to function in both the sensitization phase and effector phase of Th2-dependent allergic inflammation. T cell-specific deletion of RhoA impaired Th2 differentiation but not Th1 differentiation in vitro and prevented OVA-induced allergic inflammation in vivo with reduction in IgE level, cell infiltration in the airway and Th2 cytokine production [84]. Administration of fasudil all through the experimental period mimicked these effects of RhoA deficiency. In addition, inhalation of Y-27632 during the allergen challenge could suppress airway constriction and hypersensitivity and partially prevented cell infiltration to the airway in an OVA-induced asthma model of guinea pig [90]. These effects of Y-27632 may well be due to the suppression of enhanced calcium sensitization of airway smooth muscle contraction induced by allergen-sensitization [91], and effects of ROCK inhibition on chemotaxis of inflammatory cells. Studies using ROCK hetero-deficient mice indicate that both ROCK1 and ROCK2 in lymphocytes and nonlymphocyte cells are involved in these processes [92,93].

The more intriguing findings on the role of ROCK in Th subsets are that of ROCK2 in Th17 cells. This was first reported by the Pernis group, who found that ROCK2 is selectively activated in CD4+ T cells under Th17 skewing conditions and phosphorylates interferon regulatory factor-4 (IRF-4) to facilitate Th17 cell differentiation and that administration of ROCK inhibitor suppresses production of Th17 cytokines, IL-21 and IL-17, and ameliorates symptoms in autoimmune model mice [94]. Concurrently, Kadmon Pharmaceuticals ran Phase 1 clinical trial of a ROCK2-selective inhibitor, KD025 [95,96]. Zanin-Zhorov et al. [96] analyzed responses of peripheral blood mononuclear cells (PBMCs) from human subjects in the above trial and found that KD025 administration in vivo significantly inhibited ex vivo secretion of IL-21 and IL-17 from activated PBMCs. They confirmed this effect in human CD4+ T cells stimulated in vitro under the Th17 skewing conditions, and found that it is through suppression of STAT3 phosphorylation. Intriguingly, while KD025 suppresses Th17 differentiation through decreased STAT3 phosphorylation, it accelerates regulatory T cell (Treg) differentiation through enhanced STAT5 phosphorylation. The effect of KD025 to suppress IL-17 and IL-21 production was then confirmed in PBMCs from patients with rheumatoid arthritis, graft-versus-host disease, systemic lupus erythematosus and inflammatory bowel diseases [96–99]. Further, recent Phase 2 studies showed that oral administration of KD025 reduces clinical scores in psoriasis patients with concomitant decrease in plasma levels of IL-17 and IL-23 and increase in that of IL-10 [100].

FEBS Letters 592 (2018) 1763–1776 © 2018 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies
Cancer

Since many dbl-containing Rho GEFs were isolated by transformation assay of cultured fibroblasts [101] and Rho-GAP domain-containing DLC-1 (Deleted in Liver Cancer-1) is downregulated in various tumors and is regarded as a tumor suppressor [102], Rho GTPases have been implicated in cell transformation and oncogenesis. Indeed, earlier works showed requirement of Rho GTPases in Ras-mediated cell-transformation [103]. Notably, while these studies used GTPase-deficient G14V or Q63L in RhoA and G12V or Q61L Rac1 analogous to oncogenic Ras mutations, such mutations in Rho GTPases have not been detected in clinical cancer. On the contrary, fast cycling P29S, P29L, and P29Q mutations in Rac1 have been identified by high-throughput sequencing of clinical human cancers [104–106], the G17V RhoA mutation frequent found in T cell lymphomas [107,108] and the Y42C RhoA mutation recurrently in diffuse gastric cancer [109]. Since biochemical properties of these RhoA mutation are not clear, how these RhoA mutations induces oncogenesis is an interesting question to be solved [110]. In addition to these mutations in Rho GTPases, more than 600 somatic coding mutations in ROCK1 and ROCK2 have been identified in human cancers and downregulation of miRNAs targeting ROCK1 and ROCK2, and, consequently upregulation of ROCKs has been shown in malignant tissues [111]. This enhanced ROCK signaling could facilitate cell transformation for tumor cell survival and growth. Y-27632 treatment was reported to inhibit transformation of NIH3T3 cells by Dbl and Ras [112], and conditional deletion of ROCK1 and ROCK2 in combination was shown to inhibit transformation of cells derived from Ras-driven lung tumors and Raf-driven melanomas [113]. ROCK signaling likely functions in tumor cell invasion and metastasis, which was first shown in the peritoneal tumor dissemination model [88]. Tumor cells can migrate as single cells or collectively as a cluster. Experiments in three-dimensional matrix suggest that tumor cells adopt two different modes of single-cell migratory mechanisms, Rac-mediated elongated mesenchymal migration and ROCK-mediated rounded amoeboid migration, which are interconvertible and utilized in the context-dependent manner [114]. ROCK signaling also enables tail retraction in transendothelial and transepithelial migration of tumor cells [88]. ROCK can also remodel extracellular matrix in tumor microenvironment for tumor invasion. Sanz-Moreno et al. [115] showed in collagen matrix model that increased ROCK signaling induced by cytokine contracts stromal fibroblasts to create tracks for collective migration of squamous carcinoma cells. Rath et al. [116] showed that ROCK activation in mouse pancreatic ductal adenocarcinoma cells increased their invasive growth into a three-dimensional collagen matrix by extensive induction of matrix metalloproteinases and increased matrix remodeling. These findings combined together suggest that

Fig. 3. Milestone discoveries in Rho signaling research.
Rho-ROCK signaling is not the primary cause but critical for several important phenotypes of cancer, which may be exploited therapeutically in combination with other anticancer therapies [111].

Future prospects

Although a substantial amount of work has been done since the discovery of Rho more than 30 years ago, elucidating important physiological roles of this GTPase family and their action mechanisms as described above (Fig. 3), the whole picture of the biology of Rho, how each member of the Rho family GTPases is activated under what conditions in which tissue, exerts which body function by acting on which effectors, is still far from complete. Generation and analysis of tissue-specific conditional knockout mice deficient in each member of Rho GTPases, effectors and regulatory proteins, GEFs and GAPs, could help our understanding. This is true even for each of classic Rho member, RhoA, RhoB, and RhoC. Most of the earlier studies on Rho described above have been carried out on RhoA, and it is not certain whether other Rho members exert the same actions in the cell. Although some studies suggest the redundant roles between these RhoA, RhoB, and RhoC isoforms [117,118], their different cellular localization and different regulatory modes of expression strongly suggest that they play also context- and localization-dependent distinct roles in the cell and possibly in the body [119]. For example, although these three Rho members similarly interact with Rho effectors thus far identified, RhoA, RhoB, and RhoC act on different effectors, namely ROCKi/2, integrins and formin FMNL3, respectively, and exert different functions in cancer cell migration and morphogenesis [120]. RhoB shows unique endosome localization, and is suggested to exert different functions from RhoA and RhoC [121]. Furthermore, while RhoA-null mice are embryonic lethal [122], RhoB-null and RhoC-null mice are viable [123,124]. There are also issues on atypical Rho GTPases such as Rnd proteins, RhoBTB proteins, RhoH, RhoU and RhoV [119]. More remains to be clarified on their regulatory and effector mechanisms, and again their body function. As for Rho GTPase activation, there are 70 Rho GEFs of Dbl homology and 10 DOCK homologs. Studies have been in progress elucidating what physiological context each GEF is activated and contributes to, one classic examples being p115 RhoA-GEF coupling to Gz12/13 for cell contraction [125]. Given such importance of Rho and Rho regulators and effectors in many biological processes, the studies on the dynamics of their activation and termination, that is how Rho and Rho regulators and effectors are activated at the right time and place, and how this signal propagates in the living cell in a variety of physiological processes, is an important issue. The challenge is nanoscale imaging of spatiotemporal actions of Rho-Rho effectors not only in living cultured cells but also hopefully in intact tissues or intact body. Such studies combined with the systematic analysis on the functions of Rho signaling at respective sites will help to elucidate the pictures of Rho actions in the body. Finally, our understanding on the roles of Rho and Rho effectors in pathophysiology has just begun. As illustrated by the recent discovery of the role of ROCK2 in autoimmunity and the therapeutic effects of its selective inhibitor [100], unraveling the roles of Rho and Rho effectors further in various pathophysiological settings by the above approach may reveal unappreciated therapeutic possibilities.

Acknowledgements

This work was supported in part by Grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

1 Madaule P and Axel R (1985) A novel ras-related gene family. Cell 41, 31–40.
2 Moss J and Vaughan M (1988) ADP-ribosylation of guanyl nucleotide-binding regulatory proteins by bacterial toxins. Adv Enzymol Relat Areas Mol Biol 61, 303–379.
3 Ohashi Y and Narumiya S (1987) ADP-ribosylation of a Mr 21,000 membrane protein by type D botulinum toxin. J Biol Chem 262, 1430–1433.
4 Aktories K, Weller U and Chhatwal GS (1987) Clostridium botulinum type C produces a novel ADP-ribosyltransferase distinct from botulinum C2 toxin. FEBS Lett 212, 109–113.
5 Rosener S, Chhatwal GS and Aktories K (1987) Botulinum ADP-ribosyltransferase C3 but not botulinum neurotoxins C1 and D ADP-ribosylates low molecular mass GTP-binding proteins. FEBS Lett 224, 38–42.
6 Rubin EJ, Gill DM, Boquet P and Popoff MR (1988) Functional modification of a 21-kilodalton G protein when ADP-ribosylated by exoenzyme C3 of Clostridium botulinum. Mol Cell Biol 8, 418–426.
7 Nishiki T, Matsuda H, Hiroi T, Kamata Y, Kozaki S, Narumiya S and Sakaguchi G (1990) Morphological effects of Clostridium botulinum C3 exoenzyme on cultured cells. Jpn J Med Sci Biol 43, 261–262.
8 Nishiki T, Narumiya S, Morii N, Yamamoto M, Fujiwara M, Kamata Y, Sakaguchi G and Kozaki S (1990) ADP-ribosylation of the rho/rac proteins induces growth inhibition, neurite outgrowth and acetylcholine esterase in cultured PC-12 cells. Biochem Biophys Res Commun 167, 265–272.

9 Morii N, Sekine A, Ohashi Y, Nakao K, Imura H, Fujiwara M and Narumiya S (1988) Purification and properties of the cytosolic substrate for botulinum ADP-ribosyltransferase. Identification as an Mr 22,000 guanine nucleotide-binding protein. J Biol Chem 263, 12420–12426.

10 Narumiya S, Sekine M and Fujiwara M (1988) Substrate for botulinum ADP-ribosyltransferase, Gb, has an amino acid sequence homologous to a putative rho gene product. J Biol Chem 263, 17255–17257.

11 Sekine A, Fujiwara M and Narumiya S (1989) Asparagine residue in the rho gene product is the modification site for botulinum ADP-ribosyltransferase. J Biol Chem 264, 8602–8605.

12 Chardin P, Boquet P, Madaule P, Popoff MR, Rubin EJ and Gill DM (1989) The mammalian G protein rhoC is ADP-ribosylated by Clostridium botulinum exoenzyme C3 and affects actin microfilaments in Vero cells. EMBO J 8, 1087–1092.

13 Paterson HF, Self AJ, Garrett MD, Just I, Aktories K and Hall A (1990) Microinjection of recombinant p21rho induces rapid changes in cell morphology. J Cell Biol 111, 1001–1007.

14 Ridley AJ and Hall A (1992) The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70, 389–399.

15 Didsbury J, Weber RF, Bokoch GM, Evans T and Snyderman R (1989) Rac, a novel ras-related family of proteins that are botulinum toxin substrates. J Biol Chem 264, 16378–16382.

16 Ridley AJ, Paterson HF, Johnston CL, Diekmann D and Hall A (1992) The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70, 401–410.

17 Morii N, Teru-uchi T, Tominaga T, Kumagai N, Kozaki S, Ushikubi F and Narumiya S (1992) A rho gene product in human blood platelets. II. Effects of the ADP-ribosylation by botulinum C3 ADP-ribosyltransferase on platelet aggregation. J Biol Chem 267, 20921–20926.

18 Jalink K, van Corven EJ, Hengeveld T, Morii N, Narumiya S and Moolenaar WH (1994) Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho. J Cell Biol 126, 801–810.

19 Mabuchi I, Hamaguchi Y, Fujimoto H, Morii N, Mishima M and Narumiya S (1993) A rho-like protein is involved in the organisation of the contractile ring in dividing sand dollar eggs. Zygote 1, 325–331.

20 Kishi K, Sasaki T, Kuroda S, Itoh T and Takai Y (1993) Regulation of cytoplasmic division of Xenopus embryo by rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI). J Cell Biol 120, 1187–1195.

21 Hills CS, Wynne J and Treisman R (1995) The Rho family GTPTases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. Cell 81, 1159–1170.

22 Miralles F, Posern G, Zaromityidou A and Treisman R (2003) Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 113, 329–342.

23 Posern G and Treisman R (2006) Actin’ together: serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol 16, 588–596.

24 Manser E, Leung T, Salihuddin H, Zhao ZS and Lim L (1994) A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature 367, 40–46.

25 Madaule P, Furuyashiki T, Reid T, Ishizaki T, Watanabe G, Morii N and Narumiya S (1995) A novel partner for the GTP-bound forms of rho and rac. FEBS Lett 377, 243–248.

26 Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, Morii N et al. (1996) The small GTP-binding protein Rho binds to and activates a 16 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 15, 1885–1893.

27 Watanabe G, Saito Y, Madaule P, Ishizaki T, Fujisawa K, Morii N, Mukai H, Ono Y, Kakizuka A and Narumiya S (1996) Protein kinase N (PNK) and PNK-related protein rhophilin as targets of small GTPase Rho. Science 271, 645–648.

28 Reid T, Furuyashiki T, Ishizaki T, Watanabe G, Watanabe N, Fujisawa K, Morii N, Madaule P and Narumiya S (1996) Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the rho-binding domain. J Biol Chem 271, 13556–13560.

29 Watanabe N, Madaule P, Reid T, Ishizaki T, Watanabe G, Watanabe N, Fujisawa K, Morii N, Madaule P and Narumiya S (1997) Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the rho-binding domain. J Biol Chem 271, 13556–13560.

30 Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K and Narumiya S (1996) ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 392, 189–193.

31 Leung T, Chen XQ, Manser E and Lim L (1996) The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 16, 5313–5327.
32 Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A and Kaibuchi K (1996) Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 15, 2208–2216.
33 Thumkeo D, Watanabe S and Narumiya S (2013) Physiological roles of Rho and Rho effectors in mammals. Eur J Cell Biol 92, 303–315.
34 Ishizaki T, Naito M, Fujisawa K, Maekawa M, Watanabe N, Saito Y and Narumiya S (1997) p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett 404, 118–124.
35 Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y and Kaibuchi K (1997) Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 275, 1308–1311.
36 Puyne D, Evangelista M, Yang C, Bi E, Zigmond S, Amano M, Chihara K, Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Ohashi K, Mizuno K and Narumiya S (1999) Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 285, 895–898.
37 Thumkeo D, Shimizu Y, Sakamoto S, Yamada S and Narumiya S (2005) ROCK-I and ROCK-II cooperatively regulate closure of eyelid and ventral body wall in mouse embryo. Genes Cells 10, 825–834.
38 Thumkeo D, Shinohara R, Watanabe K, Takebayashi H, Toyoda Y, Tohyama K, Ishizaki T, Furuyashiki T and Narumiya S (2011) Deficiency of mDia, an actin nucleator, disrupts integrity of neuroepithelium and causes periventricular dysplasia. PLoS One 6, e25465.
39 Nishimura T and Takeichi M (2008) Shroom3-mediated recruitment of Rho kinases to the apical cell junctions regulates epithelial and neuroepithelial planar remodeling. Development 135, 1493–1502.
40 Munjal A, Philippe JM, Munro E and Lecuit T (2015) A novel serine/threonine kinase, as a putative target for small GTP binding protein Rho, is involved in Organ Size Control, Tissue Homeostasis, and Cancer. Cell 163, 811–828.
41 Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, Oshima M, Noda Y, Atsumura F, Taketo MM and Narumiya S (2005) ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 168, 941–953.
42 Hirata K, Kikuchi A, Sasaki T, Kuroda S, Kaibuchi K and Morishita T, Tamakawa H, Yamagami K, Inui J, Morishita T, et al. (1996) Regulation of myosin light-chain phosphatase by Rho and Rho-associated kinase (Rho-kinase). J Biol Chem 271, 245–248.
43 Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, Oshima M, Noda Y, Atsumura F, Taketo MM and Narumiya S (2005) ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 168, 941–953.
44 Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, Oshima M, Noda Y, Atsumura F, Taketo MM and Narumiya S (2005) ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 168, 941–953.
45 Thumkeo D, Keel J, Ishizaki T, Hirose M, Nonomura K, Oshima H, Oshima M, Taketo MM and Narumiya S (2003) Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol 23, 5043–5055.
46 Thumkeo D, Shimizu Y, Sakamoto S, Yamada S and Narumiya S (2005) ROCK-I and ROCK-II cooperatively regulate closure of eyelid and ventral body wall in mouse embryo. Genes Cells 10, 825–834.
47 Thumkeo D, Shinohara R, Watanabe K, Takebayashi H, Toyoda Y, Tohyama K, Ishizaki T, Furuyashiki T and Narumiya S (2011) Deficiency of mDia, an actin nucleator, disrupts integrity of neuroepithelium and causes periventricular dysplasia. PLoS One 6, e25465.
48 Martin AC and Goldstein B (2014) Apical constriction: themes and variations on a cellular mechanism driving morphogenesis. Development 141, 1987–1998.
49 Nishimura T and Takeichi M (2008) Shroom3-mediated recruitment of Rho kinases to the apical cell junctions regulates epithelial and neuroepithelial planar remodeling. Development 135, 1493–1502.
50 Nishimura T, Honda H and Takeichi M (2012) Planar cell polarity links axes of spatial dynamics in neural-tube closure. Cell 149, 1084–1097.
51 Munjal A, Philippe JM, Munro E and Lecuit T (2015) A novel serine/threonine kinase, as a putative target for small GTP binding protein Rho, is involved in Organ Size Control, Tissue Homeostasis, and Cancer. Cell 163, 811–828.
Rho signaling research

S. Narumiya and D. Thumkeo

57 Ohgushi M, Minaguchi M and Sasai Y (2015) Rho-signaling-directed YAP/TAZ activity underlies the long-term survival and expansion of human embryonic stem cells. Cell Stem Cell 17, 448–461.

58 Watanabe K, Ueno M, Kamiya D, Nishiyama A, Matsumura M, Wataya T, Takahashi JB, Nishikawa S, Nishikawa S, Muguruma K et al. (2007) A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol 25, 681–686.

59 Koyanagi M, Takahashi J, Arakawa Y, Doi D, Fukuda H, Hayashi H, Narumiya S and Hashimoto N (2008) Inhibition of the Rho/ROCK pathway reduces apoptosis during transplantation of embryonic stem cell-derived neural precursors. J Neurosci Res 86, 270–280.

60 Ohgushi M, Matsumura M, Eiraku M, Murakami K, Aramaki T, Nishiyama A, Muguruma K, Nakano T, Suga H, Ueno M et al. (2010) Molecular pathway and cell state responsible for dissociation-induced apoptosis in human pluripotent stem cells. Cell Stem Cell 7, 225–239.

61 Hirose M, Ishizaki T, Watanabe N, Uehata M, Kranenburg O, Moolenaar WH, Matsumura F, Maekawa M, Bito H and Narumiya S (1998) Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells. J Cell Biol 141, 1625–1636.

62 Bito H, Furuyashiki T, Ishihara H, Shibasaki Y, Ohashi K, Mizuno K, Maekawa M, Ishizaki T and Narumiya S (2000) A critical role for a Rho-associated kinase, p160ROCK, in determining axon outgrowth in mammalian CNS neurons. Neuron 26, 431–441.

63 Duffy P, Schmandke A, Schmandke A, Sigworth J, Narumiya S, Cafferty WB and Strittmatter SM (2009) Rho-associated kinase II (ROCKII) limits axonal growth after trauma within the adult mouse spinal cord. J Neurosci 29, 15266–15276.

64 Fujita Y and Yamashita T (2014) Axon growth inhibition by RhoA/ROCK in the central nervous system. Front Neurosci 8, 338.

65 Takano T, Wu M, Nakamuta S, Naoki H, Ishizawa N, Namba T, Watanabe T, Xu C, Hamaguchi T, Yura Y et al. (2017) Discovery of long-range inhibitory signaling to ensure single axon formation. Nat Commun 8, 33.

66 Shinohara R, Thumkeo D, Kamijo H, Kaneko N, Sawamoto K, Watanabe K, Takebayashi H, Kiyonari H, Ishizaki T, Furuyashiki T et al. (2012) A role for mDia, a Rho-regulated actin nucleator, in tangential migration of interneuron precursors. Nat Neurosci 15, 373–380.

67 Tashiro A, Minden A and Yuste R (2000) Regulation of dendritic spine morphology by the rho family of small GTPases: antagonistic roles of Rac and Rho. Cereb Cortex 10, 927–938.

68 Govek EE, Newey SE, Akerman CJ, Cross JR, Van der Veken L and Van Aelst L (2004) The X-linked mental retardation protein oligophrenin-1 is required for dendritic spine morphogenesis. Nat Neurosci 7, 364–372.

69 Taoufiq Z, Eguchi K and Takahashi T (2013) Rho-kinase accelerates synaptic vesicle endocytosis by linking cyclic GMP-dependent protein kinase activity to phosphatidylinositol-4,5-bisphosphate synthesis. J Neurosci 33, 12099–12104.

70 Deguchi Y, Harada M, Shinozawa R, Lazarus M, Cherasse Y, Urade Y, Yamada D, Sekiguchi M, Watanabe D, Furuyashiki T et al. (2016) mDia and ROCK mediate actin-dependent presynaptic remodeling regulating synaptic efficacy and anxiety. Cell Rep 17, 2405–2417.

71 Lambrecht R, Farb CR and LeDoux JE (2002) Fear memory formation involves p190 RhoGAP and ROCK proteins through a GRB2-mediated complex. Neuron 36, 727–738.

72 Swanson AM, DePoy LM and Gourley SL (2017) Inhibiting Rho kinase promotes goal-directed decision making and blocks habitual responding for cocaine. Nat Commun 8, 1861.

73 Suzuki Y, Yamamoto M, Wada H, Ito M, Nakano T, Sasaki Y, Narumiya S, Shiku H and Nishikawa M (1999) Agonist-induced regulation of myosin phosphatase activity in human platelets through activation of Rho-kinase. Blood 93, 3408–3417.

74 Shimokawa H, Hiramori K, Inuma H, Hosoda S, Kishida H, Osada H, Katagiri T, Yamauchi K, Yui Y, Minamino T et al. (2002) Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 40, 751–761.

75 Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M and Takeshita A (2002) Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105, 1545–1547.

76 Shimizu T, Fukumoto Y, Tanaka S, Satoh K, Ikeda S and Shimokawa H (2013) Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice. Arterioscler Thromb Vasc Biol 33, 2780–2791.

77 Hartmann S, Ridley AJ and Lutz S (2015) The function of Rho-associated kinases ROCK1 and ROCK2 in the pathogenesis of cardiovascular disease. Front Pharmacol 6, 276.

78 Okamoto R, Li Y, Noma K, Hiroi Y, Liu PY, Taniguchi M, Ito M and Liao JK (2013) FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. FASEB J 27, 1439–1449.
Rho signaling research

79 Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH and Liao JK (2005) Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1 +/- haploinsufficient mice. *Circulation* **112**, 2959–2965.

80 Knipe RS, Tager AM and Liao JK (2015) The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. *Pharmacol Rev* **67**, 103–117.

81 Tybulewicz VL and Henderson RB (2007) Rho family GTPases and their regulators in lymphocytes. *Nat Rev Immunol* **9**, 630–644.

82 Henning SW, Galandrini R, Hall A and Cantrell DA (1997) The GTPase Rho has a critical regulatory role in thymus development. *EMBO J* **16**, 2397–2407.

83 Corre I, Gomez M, Vielkind S and Cantrell DA (2001) Analysis of thymocyte development reveals that the GTPase RhoA is a positive regulator of T cell receptor responses in vivo. *J Exp Med* **194**, 903–914.

84 Yang J-Q, Kalim KW, Li Y, Zhang S, Hinge A, Filippi MD, Zheng Y and Guo F (2016) RhoA orchestres glycolysis for TH2 cell differentiation and allergic airway inflammation. *J Allergy Clin Immunol* **137**, 231–245.

85 Heasman SJ, Carlin LM, Cox S, Ng T and Ridley AJ (2010) Coordinated RhoA signaling at the leading edge and uropod is required for T cell transendothelial migration. *J Cell Biol* **190**, 553–563.

86 Worthylake RA, Lemoine S, Watson JM and Burridge K (2001) RhoA is required for monocyte tail retraction during transendothelial migration. *J Cell Biol* **154**, 147–160.

87 Yoshinaga-Ohara N, Takahashi A, Uchiyama T and Sasada M (2002) Spatiotemporal regulation of moesin phosphorylation and rear release by Rho and serine/threonine phosphatase during neutrophil migration. *Exp Cell Res* **278**, 112–122.

88 Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T and Narumiya S (1999) An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. *Nat Med* **5**, 221–225.

89 Ricker E, Chowdhury L, Yi W & Pernis AB (2016) The RhoA-ROCK pathway in the regulation of T and B cell responses. *F1000Res* **5**, 2295.

90 Schaafsma D, Bos IS, Zuidhof AB, Zaagsma J and Meurs H (2008) The inhaled Rho kinase inhibitor Y-27632 protects against allergen-induced acute bronchoconstriction, airway hyperresponsiveness, and inflammation. *Am J Physiol Lung Cell Mol Physiol* **295**, L214–L219.

91 Chiba Y, Takada Y, Miyamoto S, MitsuiSaito M, Karaki H and Misawa M (1999) Augmented acetylcholine-induced, Rho-mediated Ca2+ sensitization of bronchial smooth muscle contraction in antigen-induced airway hyperresponsive rats. *Br J Pharmacol* **127**, 597–600.

92 Zhu M, Liu PY, Kasahara DI, Williams AS, Verbout NG, Halayko AJ, Fedulov A, Shoji T, Williams ES, Noma K *et al.* (2011) Role of Rho kinase isoforms in murine allergic airway responses. *Eur Respir J* **38**, 841–850.

93 Kasahara DI, Mathews JA, Ninin FM, Wurmbbrand AP, Liao JK and Shore SA (2017) Role of ROCK2 in CD4+ cells in allergic airways responses in mice. *Clin Exp Allergy* **47**, 224–235.

94 Biswas PS, Gupta S, Chang E, Song L, Storzaker RA, Liao JK, Bhagat G and Perini AB (2010) Phosphorylation of Irf4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. *J Clin Invest* **120**, 3280–3295.

95 Lee JH, Zheng Y, von Bornstadt D, Wei Y, Balcioglu A, Daneshmand A, Yalcin N, Yu E, Herisson F, Atalay YB *et al.* (2014) Selective ROCK2 inhibition in focal cerebral ischemia. *Ann Clin Transl Neurol* **1**, 2–14.

96 Zalin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, Depoil D, Rao N, Liu B, Wei J *et al.* (2014) Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. *Proc Natl Acad Sci USA* **111**, 16814–16819.

97 Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, Vulic A, Luznik L, MacDonald KK, Hill GR *et al.* (2016) Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. *Blood* **127**, 2144–2154.

98 Rozo C, Chinenov Y, Maharaj RK, Gupta S, Leuenberger L, Kirou KA, Bykerk VP, Goodman SM, Salmon JE and Pernis AB (2017) Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE. *Ann Rheum Dis* **76**, 740–747.

99 Yang W, Zhou G, Yu T, Chen L, Yu L, Guo Y, Cong Y and Liu Z (2017) Critical role of ROCK2 activity in facilitating mucosal CD4+ T cell activation in inflammatory bowel disease. *J Autoimmun* **89**, 125–138.

100 Zalin-Zhorov A, Weiss JM, Trzeciak A, Chen W, Zhang J, Nyuydzefe MS, Arencibia C, Polimera S, Schueller O, Fuentes-Duculan J *et al.* (2017) Cutting edge: selective oral ROCK2 inhibitor reduces clinical scores in patients with psoriasis vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10. *J Immunol* **198**, 3809–3814.

101 Cook DR, Rossman KL and Der CJ (2014) Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease. *Oncoogene* **33**, 4021–4035.

102 Kim TY, Vigil D, Der CJ and Juliano RL (2009) Role of DLC-1, a tumor suppressor protein with RhoGAP
activity, in regulation of the cytoskeleton and cell motility. *Cancer Metastasis Rev* **28**, 77–83.

103 Zohn IM, Campbell SL, Khostrav-Far R, Rossman KL and Der CJ (1998) Rho family proteins and Ras transformation: the RHOad less traveled gets congested. *Oncogene* **17**, 1415–1438.

104 Hodies E, Watson IR, Kryukov GV, Arol ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C et al. (2012) A landscape of driver mutations in melanoma. *Cell* **150**, 251–263.

105 Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiochi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M et al. (2012) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. *Nat Genet* **44**, 1006–1114.

106 Kawazu M, Ueno T, Kontani K, Ogita Y, Ando M, Fukumura K, Yamato A, Soda M, Takeuchi K, Miki Y et al. (2013) Transforming mutations of RAC guanosine triphosphatases in human cancers. *Proc Natl Acad Sci USA* **110**, 3029–3034.

107 Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, Kim SC, Lee B, Rho K, Lee JE et al. (2014) A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. *Nat Genet* **46**, 371–375.

108 Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraiishi Y, Ishii R, Miyake Y, Muto H, Tsuyama N, Sato-Otsubo A, Okuno Y et al. (2014) Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. *Nat Genet* **46**, 171–175.

109 Kakiucli M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, Yamamoto S, Tatsuno K, Katoh H, Watanabe Y et al. (2014) Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. *Nat Genet* **46**, 583–587.

110 Olson MF (2018) Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors. *Small GTPases* **12**, 1–13.

111 Wei L, Surma M, Shi S, Lambert-Cheatham N and Shi J (2016) Novel insights into the roles of Rho kinase in cancer. *Arch Immunol Ther Exp (Warsz)* **64**, 259–278.

112 Sahai E, Ishizaki T, Narumiya S and Treisman R (1999) Transformation mediated by RhoA requires activity of ROCK kinases. *Curr Biol* **9**, 136–145.

113 Kümper S, Mardakheh FK, McCarthy A, Yeo M, Stamp GW, Paul A, Worboys J, Sadok A, Jørgensen C, Guichard S et al. (2016) Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis. *Elife* **5**, e12994.

114 Sadok A and Marshall CJ (2014) Rho GTPases: masters of cell migration. *Small GTPases* **5**, e29710.

115 Sanz-Moreno V, Gaggioli C, Yeo M, Albrengues J, Wallberg F, Viros A, Hooper S, Mitter R, Féraud CC, Cook M et al. (2011) ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. *Cancer Cell* **20**, 229–245.

116 Rath N, Morton JP, Julian L, Helbig L, Kadir S, McGhee EJ, Anderson KI, Kalna G, Mullin M, Pinho AV et al. (2017) ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. *EMBO Mol Med* **9**, 198–218.

117 Melendez J, Stengel K, Zhou X, Chauhan BK, Debidda M, Andreason P, Lang RA and Zheng Y (2011) RhoA GTPase is dispensable for actomyosin regulation but is essential for mitosis in primary mouse embryonic fibroblasts. *J Biol Chem* **286**, 15132–15137.

118 König V, Jennings R, Vogl T, Horsthemke M, Bach AC, Xu Y, Grobe K, Brakebusch C, Schwab A, Bähler M et al. (2014) Mouse macrophages completely lacking RhoA subfamily GTPases (RhoA, RhoB and RhoC) have severe lamellipodial retraction defects, but robust chemotactic navigation and altered motility. *J Biol Chem* **289**, 30772–30784.

119 Ridley AJ (2016) Open questions: what about the “other” Rho GTPases? *BMC Biol* **14**, 64.

120 Ridley AJ (2013) RhoA, RhoB and RhoC have different roles in cancer cell migration. *J Microsc* **251**, 242–249.

121 Adamson P, Paterson HF and Hall A (1992) Intracellular localization of the P21Rho proteins. *J Cell Biol* **119**, 617–627.

122 Pedersen E and Brakebusch C (2012) Rho GTPase function in development: how in vivo model changes our view. *Exp Cell Res* **318**, 1779–1787.

123 Vega FM and Ridley AJ (2016) The RhoB small GTPase in physiology and disease. *Small GTPases* **22**, 1–10.

124 Hakem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, Khokha R and Mak TW (2005) RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. *Genes Dev* **19**, 1974–1979.

125 Rossman KL, Der CJ and Sondek J (2005) GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. *Nat Rev Mol Cell Biol* **6**, 167–180.